摘要
目的探讨利培酮与阿立哌唑对阿尔茨海默病伴精神障碍患者糖脂代谢的影响。方法将128例阿尔茨海默病伴精神障碍患者随机分为利培酮组63例和阿立哌唑组65例。利培酮组口服利培酮2~4mg,每日一次;阿立哌唑组口服阿立哌唑10~20mg,每日一次;分别于治疗前和治疗3月后,使用简易智能精神状态表评分和阿尔茨海默病评价表-认知分量表评分评价,观察不良反应发生率;并比较空腹血糖、总胆固醇和甘油三酯的变化。结果治疗后,两组MMSE评分显著升高(P<0.05),ADAS-cog评分显著降低(P<0.05),两组评分相比无统计学意义(P>0.05);治疗后,利培酮组患者血糖指标显著升高(P<0.05),阿立哌唑组改变无统计学意义(P>0.05),利培酮组患者治疗后血糖指标较阿立哌唑组显著升高(P<0.05);治疗后,利培酮组与阿立哌唑组患者血脂指标显著升高(P<0.05),利培酮组患者治疗后血脂指指标较阿立哌唑组显著升高(P<0.05)。结论利培酮和阿立哌唑均能用于阿尔茨海默病伴精神障碍患者的治疗,且能引起糖脂代谢异常,其中阿立哌唑对糖脂代谢的影响相对较小。
Objective To investigate effect of risperidone and aripiprazole on clinical efficacy and glucose/lipid metabolism in Alzheimer disease patients with mental disorders.Methods 128 patients of Alzheimer disease with mental disorders were enrolled,and randomly divided into risperidone（63 cases）and aripiprazole group（65 cases）.Risperidone and aripiprazole group were received 2~4 mg risperidone and 10~20 mg aripiprazoleoral qn,respectively.MMSE,ADAS-cog score and glucose/lipid metabolism were determined in pre-therapy and 3-month post-treatment.Results After treatment,MMSE scores in the two groups were increased,and ADAS-cog scores were decreased（P〈0.05）,but there was no statistical difference between the two groups（P〉0.05）.After treatment,the blood glucose in the risperidone group was increased and higher than that in the aripiprazole group（P〈0.05）.However,the blood glucose showed no statistical difference between pre-and post-therapy（P〉0.05）in the aripiprazole group.After treatment,the total cholesterol and triglyceride in the two groups were increased（P〈0.05）,with the risperidone group was higher than the aripiprazole group（P〉0.05）.Conclusion Both risperidone and aripiprazole can be used to treat Alzheimer disease with mental disorders.They both cause abnormal glucose and lipid metabolism,and the effect of aripiprazole is relatively mild.
出处
《国际精神病学杂志》
2017年第6期1021-1023,共3页
Journal Of International Psychiatry
关键词
利培酮
阿立哌唑
阿尔茨海默病
精神障碍
糖脂代谢
Risperidone
Aripiprazole
Alzheimer disease
Mental disorders
Glucose/Lipid Metabolism
